 CAMBRIDGE, Mass.--BUSINESS WIRE--Epizyme, Inc. Nasdaq: EPZM, a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, hosted a call today outlining the Companys strategic vision and focus on oncology treatment with the Companys epigenetic pipeline. A link to the presentation and slideshow can be found here. The recent accelerated approvals of TAZVERIK in Epithelioid Sarcoma and Relapsed Refractory Follicular Lymphoma are, of c 